Equities analysts predict that Neuronetics Inc (NASDAQ:STIM) will report sales of $16.13 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Neuronetics’ earnings, with the lowest sales estimate coming in at $16.05 million and the highest estimate coming in at $16.20 million. Neuronetics reported sales of $13.74 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 17.4%. The firm is expected to announce its next quarterly earnings results on Tuesday, November 5th.
According to Zacks, analysts expect that Neuronetics will report full year sales of $63.99 million for the current fiscal year, with estimates ranging from $63.88 million to $64.10 million. For the next financial year, analysts anticipate that the firm will report sales of $76.87 million, with estimates ranging from $76.70 million to $77.03 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that follow Neuronetics.
Neuronetics (NASDAQ:STIM) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.43) by $0.04. The company had revenue of $16.57 million for the quarter, compared to analysts’ expectations of $15.80 million. Neuronetics had a negative net margin of 43.85% and a negative return on equity of 37.75%.
A number of brokerages recently issued reports on STIM. Zacks Investment Research upgraded shares of Neuronetics from a “sell” rating to a “hold” rating in a research note on Wednesday, May 8th. ValuEngine cut shares of Neuronetics from a “buy” rating to a “hold” rating in a research note on Thursday, June 27th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $31.60.
Shares of Neuronetics stock opened at $10.00 on Wednesday. The company has a market cap of $182.81 million, a PE ratio of -3.72 and a beta of 0.97. The stock has a 50-day moving average price of $11.78. Neuronetics has a 1 year low of $8.90 and a 1 year high of $39.39. The company has a current ratio of 6.10, a quick ratio of 5.95 and a debt-to-equity ratio of 0.51.
In other Neuronetics news, insider Daniel Guthrie sold 3,685 shares of the company’s stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $14.53, for a total transaction of $53,543.05. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 12.00% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently bought and sold shares of the business. Advisor Group Inc. bought a new position in Neuronetics during the 4th quarter valued at about $27,000. BNP Paribas Arbitrage SA bought a new position in Neuronetics during the 1st quarter valued at about $41,000. Bank of America Corp DE lifted its stake in Neuronetics by 967.7% during the 4th quarter. Bank of America Corp DE now owns 5,787 shares of the company’s stock valued at $111,000 after acquiring an additional 5,245 shares during the period. Rhumbline Advisers bought a new position in Neuronetics during the 1st quarter valued at about $204,000. Finally, Millennium Management LLC bought a new position in Neuronetics during the 4th quarter valued at about $303,000. Institutional investors and hedge funds own 81.15% of the company’s stock.
Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.
Read More: What is the Rule of 72?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.